Product Description
novel recombinant human/mouse chimeric epidermal growth factor receptor (EGFR) monoclonal antibody
Mechanisms of Action: EGFR Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shanghai Zhangjiang Biotechnology Limited Company
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description

Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
---|---|---|---|---|---|---|---|
CTR20170701 | P3 |
Active, not recruiting |
Colorectal Cancer |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
---|---|---|
06/26/2024 |
News Article |
Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA |